NovAliX is a fully integrated drug discovery CRO supporting therapeutic programs from target identification to the delivery of preclinical candidates. Founded in 2002 and based in Strasbourg, France, with around 430 researchers, NovAliX has four sites that allow it to provide innovative and flexible drug discovery solutions and collaborative models.
 
NovAliX enables successful discovery programs through an award-winning team of medicinal chemistry and pharmacology scientists, and a variety of screening and characterization technologies, including an outstanding DNA-encoded library platform and a comprehensive portfolio of biophysical techniques, including an in-house cryo-EM facility.